NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis and BGI Group subsidiary MGI said today they plan to codevelop next-generation sequencing-based in vitro diagnostic assays for microbial infections.

The two firms have signed a broad memorandum of understanding to develop IVD assays targeting an array of pathogens and genetic and antibiotic resistance markers. The firms plan to combine Curetis' PCR platform, the Unyvero L4 Lysator, with MGI's SP100 Sample Preparation System and MGISeq NGS sequencers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.